Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07767110 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07767110 · ClinicalTrials.gov record · last posted 2026-08-18

Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response

Study acronym: TIGER-1
StatusNot Yet Recruiting
PhasePhase 1/2
Started2026-12
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
Open-label, dose-escalating, Phase 1/2a trial of Large Surface Area Microparticle (LSAM)-Cisplatin to treat participants with diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG), via stereotactic infusion under intraoperative magnetic resonance imaging (MRI) guidance.

Protocol amendment history 1 change detected by DataLookout

2026-08-19
Primary endpoint(s) modified
WasNumber of Subjects With Treatment Emergent Adverse Events (Safety and Tolerability)
NowNumber of Participants With Treatment Emergent Adverse Events (Safety and Tolerability)
Trial Details
NCT Number NCT07767110
Lead Sponsor NanOlogy, LLC
Collaborators: WEP Clinical
Conditions Diffuse Midline Glioma (DMG), Diffuse Intrinsic Pontine Glioma (DIPG), Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Enrollment 20 participants
Start Date 2026-12
Primary Completion 2029-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-18